Today, Nice releases guidelines on treatment for type 2 diabetes.
Patients now have the option to recieve cost effective treatment by combining once-daily liraglutide with two oral anti-diabetic tablets.
The recommendation is for patients with a Body Mass Index (BMI) above 35 however, it may be used in some patients with a BMI below 35.
Further information will be released by NICE in support of this new treatment option.
The current guidelines state that NICE do not recommend the liraglutide 1.8 mg dose. NICE and Novo Nordsk soon plan to discuss the benefits of this treatment.
The Managing Director of Novo Nordisk Limited
Viggo Birch, says “We are very encouraged by the preliminary recommendation from NICE regarding the use of liraglutide 1.2 mg and that NICE have seen the value of liraglutide and the major benefits that it has for patients with type 2 diabetes. We look forward to the next stage of discussions with NICE.”
